Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2026 on ...

“Congratulations on your loyalty and commitment, and above all, for dedicating an entire lifetime to our Real Madrid,” declared the president during the insignia award ceremony. “As the president of ...

Fintel reports that on April 7, 2026, Citigroup downgraded their outlook for Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral. Analyst Price Forecast Suggests 22.54% Upside As of March 27, 2026, ...

Longleaf Partners, managed by Southeastern Asset Management, released its fourth-quarter 2025 investor letter for “Longleaf Partners Global Fund”. A copy of the letter can be downloaded here. The Fund ...

DALLAS, TX, UNITED STATES, March 19, 2026 /EINPresswire.com/ — Massive Bio today announced the launch of NexusPulse™, a real-time AI signal engine that helps ...

Bio-Rad Laboratories shares fell as the company faces margin pressure related to declining academic research funding. The stock slipped 10.6% to $261.43 Friday. Shares are down 14% over the past 12 ...

Chief Executive Officer — Norman Schwartz President and Chief Operating Officer — Jonathan DiVincenzo Executive Vice President and Chief Financial Officer — Roop Lakkaraju Yong Chung: Good afternoon, ...

HERCULES, Calif. (AP) — HERCULES, Calif. (AP) — Bio-Rad Laboratories Inc. (BIO) on Thursday reported fourth-quarter net income of $720 million, after reporting a loss in the same period a year earlier ...

After Generation Bio telegraphed plans to lay off 90% of its staff this summer, Xoma Royalty has come knocking to bring yet another ailing biotech into its fold. Xoma, which styles itself as a ...